Clinical Trial Search

Primary: Overall Objective Response — 3; 29; 39 participants

Primary: Progression Free Survival — 8.2 months

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants

Primary: Overall Pathological Response Rate — 57.7 % of participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS

Primary: Response Rate — 11 percentage of participants

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Median Overall Survival — 13.9 months

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants

Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg

Primary: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib — -0.29; 0.128 fold change

Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants

Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants

Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants

Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time — -0.036; -0.041; 1.516 log2(fold change)

Primary: Urinary Isothiocyanates Levels — 10.4; 4.3 mM — p=0.28

Primary: Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of…

Primary: Complete Tumor Response Defined as the Absence of New Tumors — 64.1 percentage of participants

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)

Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months

Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients

Primary: Treatment Completion Rate — 67; 53 percentage of participants

Primary: Feasibility — 8; 15 participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01